Streetbeat News

ANTX

AN2 Therapeutics, Inc.

https://www.an2therapeutics.com

Industry

Biotechnology

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Open

1.48

Mkt cap

43M

Volume

156K

High

1.48

P/E Ratio

-0.72

52-wk high

22.22

Low

1.43

Div yield

N/A

52-wk low

0.87

AN2 Therapeutics, Inc. (Nasdaq: ANTX) reported its Q3 2024 financial results and provided an update on the EBO-301 trial, highlighting progress in its boron chemistry pipeline. The company focuses on developing novel small molecule therapeutics.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

AN2 Therapeutics has received a continuation grant from the Bill & Melinda Gates Foundation to further its research on boron-based therapies for tuberculosis and malaria.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:03 am

Levi Strauss shares dropped over 10% in pre-market trading after reporting better-than-expected earnings but missing sales estimates for Q3. The company provided a fiscal year 2024 earnings forecast slightly below analyst expectations. Several other stocks experienced significant pre-market movements.

Portfolio Pulse from Avi Kapoor

October 03, 2024 | 9:24 am

AN2 Therapeutics has adopted a limited duration stockholder rights plan, set to expire on August 15, 2025, in response to BML Investment Partners acquiring 19.3% of its common stock. The plan aims to prevent any entity from acquiring 20% or more of the company's stock without triggering the rights plan.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 11:04 am

The article discusses recent insider transactions in three penny stocks: Reneo Pharmaceuticals, AN2 Therapeutics, and Citizens. Insiders buying shares can indicate confidence in the company's prospects. Reneo Pharmaceuticals and AN2 Therapeutics both posted quarterly losses, while Citizens reported better-than-expected financial results.

Portfolio Pulse from Avi Kapoor

August 15, 2024 | 11:23 am

AN2 Therapeutics (NASDAQ:ANTX) reported a Q2 EPS loss of $(0.48), beating the analyst consensus estimate of $(0.59) by 18.64%. This represents a 40.74% improvement over the $(0.81) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:05 pm

U.S. stocks traded mixed with the Nasdaq Composite gaining over 50 points. Crude oil prices rose, and the number of active U.S. oil rigs increased by three. Blend Labs, Doximity, and Iteris shares surged following positive financial results and acquisition news, while AN2 Therapeutics, Vicinity Motor, and Meta Materials saw significant declines due to negative developments.

Portfolio Pulse from Avi Kapoor

August 09, 2024 | 6:38 pm

US stocks edged lower with the Dow Jones, NASDAQ, and S&P 500 all falling slightly. EchoStar Corporation shares tumbled 16% after reporting worse-than-expected Q2 results. FSD Pharma, Iteris, and Hyzon Motors saw significant gains, while AN2 Therapeutics, Vicinity Motor, and Meta Materials experienced substantial declines.

Portfolio Pulse from Avi Kapoor

August 09, 2024 | 4:29 pm

AN2 Therapeutics (NASDAQ:ANTX) announced the termination of its Phase 2/3 study of epetraborole for lung disease due to lackluster data. The company will also reduce its workforce by 50% and expects to incur $2-$3 million in charges. ANTX stock dropped 60.2% following the news.

Portfolio Pulse from Vandana Singh

August 09, 2024 | 4:15 pm

AN2 Therapeutics shares are trading lower after the company announced the discontinuation of its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.